177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II treatment protocol offering 177Lu-DOTATATE therapy for somatostatin
receptor expressing cancers including, but not limited to, those arising from the neural
crest and involving such organs as the lungs, breast, gastrointestinal tract, skin and
endocrine (examples: pheochromocytoma, medullary carcinoma of the thyroid, non radioiodine
avid differentiated thyroid cancer, melanoma, renal cell, Merkel cell, paraganglioma, small
cell lung, Carcinoid and pancreatic islet cell malignancies).